Would you consider IP chemotherapy in a BRCA positive advanced ovarian cancer patient after upfront ovarian debulking surgery to no gross residual?  

There are at least two literature sources (Naumann et al 2018 Gynecol Oncol most recently) suggesting improved survival in patients with BRCA mutations undergoing IP therapy, consistent with observations that mutated patients are more platinum sensitive. Dose intensification of platinum should there...

SOLO1 showed significant benefit with maintenance PARP inhibitor in BRCAm patients, while GOG252 failed to confirm the benefit of IP chemo.